Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aridis Pharmaceuticals, Inc. (ARDS)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
983 University Avenue 95032
Los Gatos, CA, US
Los Gatos, CA, US
CEO
Vu L. Truong
Website
aridispharma.com
IPO
2018-08-14
CIK 1614067 ISIN US0403341045
Description
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase III trials for treating lung infections caused by Staphylococcus aureus alpha toxin. Also in their pipeline is AR-320, another fully human IgG1 monoclonal antibody designed to target S. aureus alpha toxin, aiming to treat infections stemming from both methicillin-resistant (MRSA) and methicillin-susceptible S. aureus. The company's developmental efforts extend to AR-105, a fully human IgG1 mAb in Phase II trials, which is being developed to combat the gram-negative bacterium P. aeruginosa. Furthermore, AR-101, a human IgM mAb, is undergoing Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) specifically linked to P. aeruginosa serotype O11. In earlier stages, AR-401 is in preclinical development to address infections caused by Acinetobacter baumannii, and AR-201, a fully human IgG1 mAb, is in a preclinical program targeting respiratory syncytial virus. AR-501, an anti-infective therapy, is currently in Phase I/IIa clinical trials for managing chronic lung infections in patients with cystic fibrosis. Additionally, Aridis is developing AR-712 and AR-701, a combination of two fully human IgG1 mAbs, which is in Phase I/II clinical trials for treating mild to moderate COVID-19 in non-hospitalized individuals. Aridis Pharmaceuticals, Inc. was established in 2003 and is headquartered in Los Gatos, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
16.9K
Beta
-26.04
Float Shares
40.31M
Free Float %
90.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -87.88% | +0.00% | -88.89% | +0.00% | -86.67% | +100.00% | -99.89% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-40.63
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+52.3% ★ Q3'23: +99.6% (vs Q3'22)
-
FCF margin FCF growth · Biotechnology: +16.2%— Q3'23: -235.7% (vs Q3'22)
-
EBIT margin Biotechnology: +0.0%— Q3'23: -208.4% (vs Q3'22)
-
ROIC Biotechnology: -16.1%— Q3'23: +49.7% (vs Q3'22)
-
Share dilution Biotechnology: -3.4%+52.8% Q3'23: +111.4% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.21× Q3'23: -1.49× (vs Q3'22)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.76M
est: 1.72M (+59.9%)
|
1.02M
est: 1.26M (-19.0%)
|
1.00M
est: 1.50M (-33.3%)
|
—
est: 2.43M (-100.0%)
|
—
est: 2.19M (-100.0%)
|
21.40M
est.
|
7.60M
est.
|
66.55M
est.
|
110.71M
110.71M – 110.71M
+66.3% YoY
|
171.40M
171.40M – 171.40M
+54.8% YoY
|
| EBITDA |
-23.83M
est: -344.9K (-6,810.4%)
|
-28.75M
est: -252.2K (-11,299.3%)
|
-22.06M
est: -300.0K (-7,254.7%)
|
-44.43M
est: -486.4K (-9,035.1%)
|
-29.51M
est: -438.7K (-6,625.3%)
|
-4.28M
est.
|
-1.52M
est.
|
-13.31M
est.
|
-22.14M
-22.14M – -22.14M
-66.3% YoY
|
-34.28M
-34.28M – -34.28M
-54.8% YoY
|
| EBIT |
-24.12M
est: -344.9K (-6,892.5%)
|
-29.09M
est: -252.2K (-11,433.4%)
|
-22.40M
est: -300.0K (-7,367.0%)
|
-43.44M
est: -486.4K (-8,830.5%)
|
-29.99M
est: -438.7K (-6,736.3%)
|
-4.28M
est.
|
-1.52M
est.
|
-13.31M
est.
|
-22.14M
-22.14M – -22.14M
-66.3% YoY
|
-34.28M
-34.28M – -34.28M
-54.8% YoY
|
| Net Income |
-22.11M
est: -609.84M (+96.4%)
|
-29.68M
est: -67.32M (+55.9%)
|
-22.33M
est: -45.82M (+51.3%)
|
-42.28M
est: -67.04M (+36.9%)
|
-30.75M
est: -32.61M (+5.7%)
|
1.31M
est.
|
-1.69M
est.
|
27.60M
est.
|
61.97M
61.97M – 61.97M
+124.5% YoY
|
101.96M
101.96M – 101.96M
+64.5% YoY
|
| SGA |
3.87M
est: 5.43M (-28.7%)
|
6.03M
est: 3.97M (+51.7%)
|
6.45M
est: 4.72M (+36.4%)
|
7.31M
est: 7.66M (-4.6%)
|
7.16M
est: 6.91M (+3.7%)
|
67.39M
est.
|
23.93M
est.
|
209.59M
est.
|
348.64M
348.64M – 348.64M
+66.3% YoY
|
539.79M
539.79M – 539.79M
+54.8% YoY
|
| EPS |
-7.02
est: -32.48 (+78.4%)
|
-3.43
est: -3.59 (+4.3%)
|
-2.44
est: -2.44 (+0.0%)
|
-3.44
est: -3.57 (+3.6%)
|
-1.64
est: -1.74 (+5.6%)
|
0.07
est.
|
-0.09
est.
|
1.47
est.
|
3.30
3.30 – 3.30
+124.5% YoY
|
5.43
5.43 – 5.43
+64.5% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-18.66M
OE per share TTM
-0.77
Owner's Yield
-249,319.60%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
99.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
3.00
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cystic Fibrosis Foundation | 5.17M | 19.90% | 5.17M | — | 5.17M | — | CO | Delaware, USA | 2022-12-19 | ↗ |
| 2 | Jeff Easton | 3.00M | 8.30% | 3.00M | — | 3.00M | — | IN | Delaware | 2023-03-20 | ↗ |
| 3 | Lind Global Fund II LP | 3.00M | 8.30% | 3.00M | — | 3.00M | — | PN | Delaware | 2023-03-20 | ↗ |
| 4 | Lind Global Partners II LLC | 3.00M | 8.30% | 3.00M | — | 3.00M | — | OO | Delaware | 2023-03-20 | ↗ |
| 5 | Armistice Capital, LLC | 3.00M | 9.99% | — | 3.00M | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 6 | Steven Boyd | 3.00M | 9.99% | — | 3.00M | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 7 | Catalysis Partners, LLC | 676.9K | 6.10% | — | 676.9K | — | — | PN | Delaware | 2021-04-01 | ↗ |
| 8 | Francis Capital Management, LLC | 676.9K | 6.10% | — | 676.9K | — | — | IA, HC, OO | Delaware | 2021-04-01 | ↗ |
| 9 | John Francis | 676.9K | 6.10% | — | 676.9K | — | — | HC, IN | Delaware | 2021-04-01 | ↗ |
| 10 | Name of Reporting Person | 7.00 | 8.00% | 885.0K | — | 885.0K | — | — | United Kingdom | 2021-07-27 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
1
+1 vs prev Q
New positions
1
Closed positions
0
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | STRENGTHENING FAMILIES & COMMUNITIES, LLC | — -3.0K (-100.0%) | — -3.0 (-100.0%) | 0.00% -0.008 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
2.08M
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+2,078,572
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-27 | Windham-Bannister Susan Richards | Director | A-Award | A | Stock options | 200,000 | 0.06 | 12.6K | 261,000 | — | ↗ |
| 2024-06-27 | Jafri Hasan | Officer | A-Award | A | Stock options | 250,000 | 0.06 | 15.8K | 382,495 | — | ↗ |
| 2024-06-27 | HAMILTON JOHN F | Director | A-Award | A | Stock options | 200,000 | 0.06 | 12.6K | 269,040 | — | ↗ |
| 2024-06-24 | Truong Vu | Director / Officer | P-Purchase | A | Common stock purchase | 714,286 | 0.07 | 50.0K | 1,378,639 | — | ↗ |
| 2024-06-24 | Patzer Eric | Director | P-Purchase | A | Common stock purchase | 714,286 | 0.07 | 50.0K | 884,600 | — | ↗ |
| 2023-09-18 | Windham-Bannister Susan Richards | Director | A-Award | A | Stock Options | 15,000 | 0.08 | 1.2K | 73,500 | — | ↗ |
| 2023-09-18 | Truong Vu | Director / Officer | A-Award | A | Stock Options | 30,000 | 0.08 | 2.4K | 817,750 | — | ↗ |
| 2023-09-18 | Patzer Eric | Director / Officer | A-Award | A | Stock Options | 15,000 | 0.08 | 1.2K | 161,862 | — | ↗ |
| 2023-09-18 | Jafri Hasan | Officer | A-Award | A | Stock Options | 20,000 | 0.08 | 1.6K | 175,000 | — | ↗ |
| 2023-09-18 | HAMILTON JOHN F | Director | A-Award | A | Stock Options | 15,000 | 0.08 | 1.2K | 91,540 | — | ↗ |
| 2023-06-05 | Windham-Bannister Susan Richards | Director | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2023-06-05 | Truong Vu | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 0.00 | — | 752,353 | — | ↗ |
| 2023-06-05 | Patzer Eric | Director / Officer | M-Exempt | D | Restricted Stock Units | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2023-06-05 | KURLAND FRED | Officer | M-Exempt | A | Common Stock | 4,000 | 0.00 | — | 4,000 | — | ↗ |
| 2023-06-05 | Jafri Hasan | Officer | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 15,100 | — | ↗ |
| 2023-06-05 | HAMILTON JOHN F | Director | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2023-05-04 | Windham-Bannister Susan Richards | Director | A-Award | A | Stock Options | 15,000 | 0.16 | 2.4K | 58,500 | — | ↗ |
| 2023-05-04 | Truong Vu | Director / Officer | A-Award | A | Stock Options | 100,000 | 0.16 | 16.0K | 787,750 | — | ↗ |
| 2023-05-04 | Patzer Eric | Director / Officer | A-Award | A | Stock Options | 30,000 | 0.16 | 4.8K | 146,862 | — | ↗ |
| 2023-05-04 | KURLAND FRED | Officer | A-Award | A | Stock Options | 10,000 | 0.16 | 1.6K | 84,575 | — | ↗ |
| 2023-05-04 | Jafri Hasan | Officer | A-Award | A | Stock Options | 25,000 | 0.16 | 4.0K | 155,000 | — | ↗ |
| 2023-05-04 | HAMILTON JOHN F | Director | A-Award | A | Stock Options | 15,000 | 0.16 | 2.4K | 76,540 | — | ↗ |
| 2022-12-08 | Cystic Fibrosis Foundation | Director | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 5,168,732 | — | ↗ |
| 2022-12-05 | Windham-Bannister Susan Richards | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-12-05 | Truong Vu | Officer | A-Award | A | Restricted Stock Units | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-12-05 | RUFFOLO ROBERT R | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-12-05 | Patzer Eric | Officer | A-Award | A | Restricted Stock Units | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-12-05 | KURLAND FRED | Officer | A-Award | A | Restricted Stock Units | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2022-12-05 | Jafri Hasan | Officer | A-Award | A | Restricted Stock Units | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-12-05 | HAMILTON JOHN F | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-12-05 | Gibbs Craig S | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-07 | Truong Vu | Director / Officer | A-Award | A | Stock Options | 88,360 | 1.06 | 93.7K | 687,750 | — | ↗ |
| 2021-12-12 | BLECH ISAAC | Director | — | D | Warrant to Purchase Common Stock | 234,860 | 14.50 | 3.41M | 0 | — | ↗ |
| 2021-10-04 | Windham-Bannister Susan Richards | Director | A-Award | A | Stock Options | 8,500 | 3.60 | 30.6K | 43,500 | — | ↗ |
| 2021-10-04 | RUFFOLO ROBERT R | Director | A-Award | A | Stock Options | 7,000 | 3.60 | 25.2K | 49,791 | — | ↗ |
| 2021-10-04 | KURLAND FRED | Officer | A-Award | A | Stock Options | 20,000 | 3.60 | 72.0K | 74,575 | — | ↗ |
| 2021-10-04 | Jafri Hasan | Officer | A-Award | A | Stock Options | 30,000 | 3.60 | 108.0K | 120,000 | — | ↗ |
| 2021-10-04 | HAMILTON JOHN F | Director | A-Award | A | Stock Options | 9,400 | 3.60 | 33.8K | 61,540 | — | ↗ |
| 2021-10-04 | Gibbs Craig S | Director | A-Award | A | Stock Options | 7,900 | 3.60 | 28.4K | 60,040 | — | ↗ |
| 2021-09-07 | Jafri Hasan | Officer | P-Purchase | A | Common Stock | 100 | 3.97 | 397.00 | 5,100 | — | ↗ |
| 2021-09-03 | Jafri Hasan | Officer | P-Purchase | A | Common Stock | 3,009 | 4.15 | 12.5K | 3,009 | — | ↗ |
| 2021-07-27 | Truong Vu | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 5.11 | 25.6K | 737,353 | — | ↗ |
| 2021-07-27 | Patzer Eric | Director | P-Purchase | A | Common Stock | 5,175 | 4.84 | 25.0K | 702,132 | — | ↗ |
| 2021-07-27 | HAMILTON JOHN F | Director | P-Purchase | A | Common Stock | 2,000 | 4.87 | 9.7K | 2,000 | — | ↗ |
| 2021-05-12 | Truong Vu | Director / Officer | A-Award | A | Stock Options | 53,340 | 6.25 | 333.4K | 599,390 | — | ↗ |
| 2021-04-01 | Jafri Hasan | Officer | A-Award | A | Stock Options | 10,000 | 5.90 | 59.0K | 90,000 | — | ↗ |
| 2021-02-18 | Nazak Michael Adrian | Officer | M-Exempt | A | Stock Options | 20,000 | 7.84 | 156.8K | 80,000 | — | ↗ |
| 2020-12-22 | Patzer Eric | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 16,000 | 0.00 | — | 696,957 | — | ↗ |
| 2020-06-25 | Jafri Hasan | Officer | A-Award | A | Stock Options | 80,000 | 6.16 | 492.8K | 80,000 | — | ↗ |
| 2020-06-15 | Jafri Hasan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-03 | Truong Vu | Director / Officer | M-Exempt | A | Stock Options | 50,000 | 5.24 | 262.0K | 546,050 | — | ↗ |
| 2020-01-02 | Nazak Michael Adrian | Officer | M-Exempt | A | Stock Options | 20,000 | 4.45 | 89.0K | 60,000 | — | ↗ |
| 2020-01-01 | Nazak Michael Adrian | Officer | — | D | Stock Options | 40,000 | 8.50 | 340.0K | 0 | — | ↗ |
| 2019-08-13 | RUFFOLO ROBERT R | Director | A-Award | A | Stock Options | 35,000 | 8.39 | 293.7K | 42,791 | — | ↗ |
| 2019-08-13 | HAMILTON JOHN F | Director | A-Award | A | Stock Options | 35,000 | 8.39 | 293.7K | 52,140 | — | ↗ |
| 2019-08-13 | Gibbs Craig S | Director | A-Award | A | Stock Options | 35,000 | 8.39 | 293.7K | 52,140 | — | ↗ |
| 2019-07-12 | Windham-Bannister Susan Richards | Director | A-Award | A | Stock Options | 35,000 | 10.01 | 350.4K | 35,000 | — | ↗ |
| 2019-06-05 | Windham-Bannister Susan Richards | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-05 | KURLAND FRED | Officer | A-Award | A | Stock Options | 15,000 | 9.03 | 135.5K | 54,575 | — | ↗ |
| 2019-02-20 | Truong Vu | Director / Officer | A-Award | A | Stock Options | 200,000 | 8.20 | 1.64M | 496,050 | — | ↗ |
| 2018-12-05 | KURLAND FRED | Officer | A-Award | A | Stock Options | 17,000 | 8.50 | 144.5K | 39,574 | — | ↗ |
| 2018-12-05 | Dummer Wolfgang | Officer | A-Award | A | Stock Options | 25,000 | 8.50 | 212.5K | 81,094 | — | ↗ |
| 2018-08-13 | Truong Vu | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 732,352 | — | ↗ |
| 2018-08-13 | RUFFOLO ROBERT R | Director | — | D | Stock Options | 7,791 | 13.16 | 102.5K | 0 | — | ↗ |
| 2018-08-13 | Patzer Eric | Director / 10% Owner | — | D | Stock Options | 38,954 | 9.63 | 375.1K | 0 | — | ↗ |
| 2018-08-13 | Lu Shawn | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-13 | KURLAND FRED | Officer | — | D | Stock Options | 3,985 | 17.20 | 68.5K | 0 | — | ↗ |
| 2018-08-13 | HAMILTON JOHN F | Director | — | D | Stock Options | 9,349 | 17.97 | 168.0K | 0 | — | ↗ |
| 2018-08-13 | Gibbs Craig S | Director | — | D | Stock Options | 9,349 | 17.97 | 168.0K | 0 | — | ↗ |
| 2018-08-13 | Dummer Wolfgang | Officer | — | D | Stock Options | 56,094 | 17.20 | 964.8K | 0 | — | ↗ |
| 2018-08-13 | Coughlin Robert K. | Director | — | D | Stock Options | 9,349 | 17.97 | 168.0K | 0 | — | ↗ |
| 2018-06-05 | HAMILTON JOHN F | Director | — | D | Stock Options | 7,791 | 12.96 | 101.0K | 0 | — | ↗ |
| 2018-03-01 | Gibbs Craig S | Director | — | D | Stock Options | 7,791 | 2.89 | 22.5K | 0 | — | ↗ |
| 2017-12-06 | KURLAND FRED | Officer | — | D | Stock Options | 5,454 | 2.89 | 15.8K | 0 | — | ↗ |
| 2017-03-05 | Coughlin Robert K. | Director | — | D | Stock Options | 7,791 | 2.89 | 22.5K | 0 | — | ↗ |
| 2017-03-01 | Truong Vu | Director / Officer / 10% Owner | — | D | Stock Options | 77,908 | 13.16 | 1.03M | 0 | — | ↗ |
| 2017-03-01 | Patzer Eric | Director / 10% Owner | — | D | Stock Options | 77,908 | 13.16 | 1.03M | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
44.57M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Vu Truong, Ph.D. Chief Executive Officer and Chief Scientific Officer | 525.0K | 106.7K | 28.5K | — | — | — | 660.2K | 4.32% | ↗ |
| 2 | 2022 | Hasan Jafri, M.D Chief Medical Officer | 439.4K | 120.0K | 19.0K | 8.4K | — | — | 586.8K | 4.67% | ↗ |
| 3 | 2022 | Eric Patzer, Ph.D. Executive Chairman | 240.0K | — | 22.8K | — | — | — | 262.8K | 8.68% | ↗ |
| 4 | 2021 | Vu Truong, Ph.D. Chief Executive Officer and Chief Scientific Officer | 500.0K | 76.3K | — | 266.2K | — | — | 842.5K | 31.60% | ↗ |
| 5 | 2021 | Hasan Jafri, M.D. Chief Medical Officer | 422.4K | 114.8K | — | 131.5K | — | — | 669.7K | 19.63% | ↗ |
| 6 | 2021 | Hasan Jafri, M.D Chief Medical Officer | 422.4K | 114.8K | — | 131.5K | — | — | 669.7K | 19.63% | ↗ |
| 7 | 2021 | Fred Kurland Chief Financial Officer | 169.8K | — | — | 56.4K | — | — | 226.1K | 24.94% | ↗ |
| 8 | 2021 | Eric Patzer, Ph.D. Executive Chairman | 137.7K | — | — | — | — | — | 137.7K | 0.00% | ↗ |
| 9 | 2020 | Vu Truong, Ph.D. Chief Executive Officer and Chief Scientific Officer | 475.0K | 91.1K | — | 217.4K | — | — | 783.5K | 27.74% | ↗ |
| 10 | 2020 | Hasan Jafri, M.D. Chief Medical Officer | 223.7K | — | — | 407.2K | — | — | 630.9K | 64.55% | ↗ |
| 11 | 2020 | Michael A. Nazak Chief Financial Officer | 315.0K | — | — | 65.2K | — | — | 380.2K | 17.14% | ↗ |
| 12 | 2019 | Vu Truong, Ph.D. Chief Executive Officer and Chief Scientific | 450.0K | 202.5K | — | 1.22M | — | — | 1.87M | 65.10% | ↗ |
| 13 | 2019 | Vu Truong, Ph.D. Chief Executive Officer and Chief Scientific Officer | 450.0K | 202.5K | — | 1.22M | — | — | 1.87M | 65.10% | ↗ |
| 14 | 2019 | Wolfgang Dummer, M.D., Ph.D Chief Medical Officer | 309.2K | 30.0K | — | — | — | — | 339.2K | 0.00% | ↗ |
| 15 | 2019 | Fred Kurland Chief Financial Officer | 226.2K | — | — | 97.0K | — | — | 323.2K | 30.02% | ↗ |
| 16 | 2019 | Eric Patzer, Ph.D. Executive Chairman | 233.1K | — | — | — | — | — | 233.1K | 0.00% | ↗ |
| 17 | 2018 | Vu Truong, Ph.D. Chief Executive Officer and Chief Scientific Officer | 450.0K | 157.5K | — | 1.41M | — | — | 2.02M | 69.86% | ↗ |
| 18 | 2018 | Vu Truong, Ph.D. Chief Executive Officer and Chief Scientific | 450.0K | 157.5K | — | 1.41M | — | — | 2.02M | 69.86% | ↗ |
| 19 | 2018 | Wolfgang Dummer, M.D., Ph.D Chief Medical Officer | 325.0K | 30.0K | — | 829.2K | — | — | 1.18M | 70.02% | ↗ |
| 20 | 2018 | Fred Kurland Chief Financial Officer | 147.3K | — | — | 229.9K | — | — | 377.1K | 60.95% | ↗ |
| 21 | 2018 | Eric Patzer, Ph.D. Executive Chairman | 275.0K | — | — | — | — | — | 275.0K | 0.00% | ↗ |
| 22 | 2017 | Eric Patzer, Ph.D. Executive Chairman | 275.0K | — | — | 519.6K | — | — | 794.6K | 65.39% | ↗ |
| 23 | 2017 | Vu Truong, Ph.D. Chief Executive Officer and Chief Scientific Officer | 350.0K | 140.0K | — | — | — | — | 490.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vu L. Truong | Founder, Chief Executive Officer, Chief Scientific Officer & Director | 631.7K | — |
| Hasan Jafri | Chief Medical Officer | 559.4K | — |
| Eric J. Patzer | Founder & Executive Chairman | 240.0K | — |
| Jeffrey J. Fessler | Acting General Counsel | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARDS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
